Scancell’s dilemma delayed
The group touts a 72% ORR with SCIB1, but full Scope data have been pushed back into 2025.
No PRAME encore for Immatics
A 5% response rate with IMA402 monotherapy seems unlikely to turn heads.
Genmab formalises the challenge against its partner
GEN1286/PRO1286 features among the latest industry projects to enter clinical trials.
The markets stress over Nuvectis
NXP800 yields neither severe thrombocytopenia, nor any responses.
Merck & Co gets in on the bispecific act
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
